Zoetis shares soar as earnings and guidance beat expectations

Published 05/08/2025, 13:00
© Reuters.

Investing.com -- Zoetis Inc. shares surged 9.4% premarket on Tuesday after the company reported second-quarter earnings that exceeded analyst expectations and raised its full-year guidance, demonstrating strong momentum across its diverse product portfolio.

The company reported adjusted earnings per share of $1.76 for the second quarter, significantly beating the analyst estimate of $1.62. Revenue came in at $2.46 billion, above the consensus estimate of $2.41 billion and representing a 4% increase compared to the same quarter last year. On an organic operational basis, revenue grew 8% YoY.

"Zoetis delivered a strong broad-based performance in the second quarter of 2025, with 8% organic operational revenue growth," said Kristin Peck, Chief Executive Officer of Zoetis. "Our consistent results across economic and competitive cycles reflect the strength of our innovation engine, the breadth of our diversified portfolio and the discipline of our execution."

In the U.S. segment, revenue reached $1.4 billion, increasing 4% compared to the second quarter of 2024, with companion animal products growing 9%, driven primarily by Simparica Trio and the company’s dermatology portfolio. International segment revenue rose 3% to $1.1 billion, with companion animal products growing 8% on both a reported and operational basis.

The company raised its full-year 2025 guidance, now expecting revenue between $9.45 billion and $9.6 billion, representing organic operational growth of 6.5% to 8.0%. This outlook exceeds the consensus estimate of $9.497 billion. Zoetis also increased its adjusted EPS guidance to $6.30-$6.40, above analyst expectations of $6.21.

The improved outlook reflects Zoetis’ strong first-half performance, disciplined execution, and effective cost management. The company continues to advance its product pipeline with new approvals and geographic expansions across both companion animal and livestock segments.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.